Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Anita J. Brogan"'
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 3, Pp 533-542 (2017)
Trivalent inactivated influenza vaccines (IIV3s) protect against 2 A strains and one B lineage; quadrivalent versions (IIV4s) protect against an additional B lineage. The objective was to assess projected health and economic outcomes associated with
Externí odkaz:
https://doaj.org/article/d2fd59cc55cb4e9198decb60433a73cc
Autor:
Donal Bisanzio, Ashley E. Davis, Sandra E. Talbird, Thierry Van Effelterre, Laurent Metz, Maren Gaudig, Valérie Oriol Mathieu, Anita J. Brogan
Publikováno v:
Vaccine. 41:684-693
Nonpharmaceutical interventions (NPI) and ring vaccination (i.e., vaccination that primarily targets contacts and contacts of contacts of Ebola cases) are currently used to reduce the spread of Ebola during outbreaks. Because these measures are typic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a55269d40f31ab1c6879f704799bd3c9
https://doi.org/10.1016/j.vaccine.2022.11.036
https://doi.org/10.1016/j.vaccine.2022.11.036
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0203293 (2018)
METHODS:Ninety-six-week costs for antiretroviral drugs, adverse event management, and HIV care for individuals initiating RAL, ATV/r, or DRV/r as first-line therapy for HIV-1 infection were estimated using an economic model. Efficacy and safety data
Externí odkaz:
https://doaj.org/article/19af58ce47ff4dde8e4740f4fd087353
Autor:
Anita J Brogan, Sandra E Talbird, James R Thompson, Jeffrey D Miller, Jaime Rubin, Baris Deniz
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e90295 (2014)
To explore the expected long-term health and economic outcomes of telaprevir (TVR) plus peginterferon alfa-2a and ribavirin (PR), a regimen that demonstrated substantially increased sustained virologic response (SVR) compared with PR alone in adults
Externí odkaz:
https://doaj.org/article/78dd742c199944178368b67eb3e5e99a
Publikováno v:
PharmacoEconomics. 39(4)
Ibalizumab-uiyk (ibalizumab) is a first-in-class, long-acting, postattachment HIV-1 inhibitor for adults with multidrug-resistant (MDR) HIV-1 infection. This analysis examines the cost-effectiveness and budget impact of ibalizumab treatment for this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::430a85646faa6dfdbaa9a183d67deb6c
https://pubmed.ncbi.nlm.nih.gov/33532919
https://pubmed.ncbi.nlm.nih.gov/33532919
Autor:
Erik, Smets, Anita J, Brogan, Andrew, Hill, Ines, Adriaenssen, Anthony W, Sawyer, Pere, Domingo-Pedrol, Joana, Gostkorzewicz, Francisco, Ledesma
Publikováno v:
Enfermedades infecciosas y microbiologia clinica. 31(7)
GESIDA (AIDS Study Group) has proposed preferred regimens of antiretroviral treatment as initial therapy in HIV infected patients. The objective of this analysis is to compare the costs and effectiveness of darunavir/r QD and other ritonavir-boosted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f2ca9c53953223ca243111c849a9b52a
https://pubmed.ncbi.nlm.nih.gov/23260386
https://pubmed.ncbi.nlm.nih.gov/23260386
Publikováno v:
American journal of preventive medicine. 37(5)
Postexposure prophylaxis (PEP) with oseltamivir (Tamiflu) has been shown to be effective and is approved in children exposed to a case of influenza in a household setting. Given limited healthcare budgets, it is important to understand the costs and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9ca1a7532de344565060edefd091d518
https://pubmed.ncbi.nlm.nih.gov/19840692
https://pubmed.ncbi.nlm.nih.gov/19840692